Isavuconazonium - Basilea Pharmaceutica

Drug Profile

Isavuconazonium - Basilea Pharmaceutica

Alternative Names: AK-1820; ASP-9766; BAL-8557; BAL-8557-000; BAL-8557-002; BAL-9557; Cresemba; Isavuconazole - Basilea Pharmaceutica; Isavuconazonium chloride; Isavuconazonium sulfate; Isavuconazonium sulphate

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Basilea Pharmaceutica
  • Developer Asahi Kasei Pharma Corp; Astellas Pharma; Basilea Pharmaceutica; Grupo Biotoscana; Hikma Pharmaceuticals
  • Class Antifungals; Nitriles; Pyridines; Small molecules; Triazoles
  • Mechanism of Action 14-alpha demethylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Candidiasis; Aspergillosis; Candidaemia; Zygomycosis
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Aspergillosis; Zygomycosis
  • Phase III Candidiasis; Mycoses
  • Phase I Haematological malignancies

Most Recent Events

  • 04 Oct 2018 Registered for Aspergillosis in Argentina (IV)
  • 04 Oct 2018 Registered for Aspergillosis in Argentina (PO)
  • 04 Oct 2018 Registered for Zygomycosis in Argentina (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top